Rubicon Research (NSE:RUBICON) Marketable Securities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:RUBICON Rubicon Research Ltd NSE:RUBICON
19 GF Score
Price ₹1,828.80
! 5 Warning Signs
View Full Analysis

What is Rubicon Research Marketable Securities?

Rubicon Research NSE:RUBICON +0.36% 19 Marketable Securities is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:RUBICON with a GF Score™ of 19/100. The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Rubicon Research's Marketable Securities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Rubicon Research's annual Marketable Securities increased from Mar. 2024 (₹10 Mil) to Mar. 2025 (₹12 Mil) and increased from Mar. 2025 (₹12 Mil) to Mar. 2026 (₹1,506 Mil).

Rubicon Research  (NSE:RUBICON) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Rubicon Research Marketable Securities Related Terms

Rubicon Research Marketable Securities Historical Data

* Premium members only.

The historical data trend for Rubicon Research's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rubicon Research Marketable Securities Chart

Rubicon Research Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Marketable Securities
6.27 9.60 11.59 1,505.54

Rubicon Research Quarterly Data
Mar23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only 11.59 14.91 0.00 1,505.54 0.00
NSE:RUBICON
19GF Score
Rubicon Research Ltd NSE:RUBICON
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rubicon Research Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₹0 Mil mean?
Rubicon Research (NSE:RUBICON) has a Marketable Securities of ₹0 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Rubicon Research and its competitors.
Is Rubicon Research's Marketable Securities too high?
Rubicon Research's current Marketable Securities is ₹0 Mil. Overall, Rubicon Research has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's Marketable Securities compare to LLY and JNJ?
Rubicon Research's Marketable Securities of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Rubicon Research and its competitors. Rubicon Research's current Marketable Securities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current Marketable Securities of ₹0 Mil. The current Marketable Securities is ₹0 Mil. Rubicon Research's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current Marketable Securities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rubicon Research Business Description

Other Exchanges 544578:India
Address Road No. 33, MedOne House, B-75, Wagle Estate, Thane West, Thane, MH, IND, 400 604
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
19GF Score

Get the complete analysis for NSE:RUBICON

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,828.80
Price